Headlines about Argos Therapeutics (NASDAQ:ARGS) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.9684476248454 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Investor’s Alert (EPS in Focus) – Argos Therapeutics Inc (NASDAQ … – Stocks Market Cap (stocksmarketcap.com)
- Argos Therapeutics, Inc. (ARGS) locked -68.12% below comparative SMA-200 – The Stocks News (press release) (thestocksnews.com)
- Is The Stock Risky? (Beta Analysis) – Argos Therapeutics Inc (NASDAQ: ARGS) – Stocks Pen (stockspen.com)
- Stock’s Technical Picture to Focus on Argos Therapeutics, Inc. (ARGS) – Wall Street Morning (wallstreetmorning.com)
- Argos Therapeutics, Inc. (NASDAQ:ARGS) – Eye-Catching Shares – Nasdaq Journal (nasdaqjournal.com)
Shares of Argos Therapeutics (ARGS) traded down $0.05 during trading on Friday, hitting $1.24. 249,133 shares of the company traded hands, compared to its average volume of 695,840. The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29. The company has a market cap of $7.61, a price-to-earnings ratio of -0.05 and a beta of 1.36. Argos Therapeutics has a 52 week low of $1.23 and a 52 week high of $24.00.
TRADEMARK VIOLATION WARNING: “Argos Therapeutics (ARGS) Earns News Sentiment Rating of 0.24” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/18/argos-therapeutics-args-earns-daily-media-impact-rating-of-0-24/2010443.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.